Atossa Therapeutics (ATOS) EBT (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly EBT of -$9.6 million for Q1 2026, down 42.74% year-over-year from -$16.7 million in Q1 2025, and up 12.33% quarter-over-quarter from -$10.9 million in Q4 2025.
Atossa Therapeutics (ATOS) EBT (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported EBT for 16 consecutive years, with -$9.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT fell 42.74% year-over-year to -$9.6 million; the TTM figure through Mar 2026 stood at -$37.6 million (down 42.88% YoY), while the FY2025 annual figure was -$34.8 million, down 36.33% from the prior year.
- EBT climbed to -$9.6 million in Q1 2026 per ATOS's latest filing, from -$10.9 million in the prior quarter.
- Across five years, EBT topped out at -$4.8 million in Q1 2022 and bottomed at -$10.9 million in Q4 2025.
- Historically, EBT has averaged -$7.5 million across 5 years, with a median of -$7.2 million in 2024.
- Annual changes were most pronounced in 2024 — EBT surged 38.46% — and 2025, when it slumped 72.32%.
- Atossa Therapeutics' EBT stood at -$7.5 million in 2022, then decreased by 3.51% to -$7.8 million in 2023, then rose by 18.15% to -$6.3 million in 2024, then plunged by 72.32% to -$10.9 million in 2025, then gained by 12.33% to -$9.6 million in 2026.
- Business Quant data shows ATOS's EBT at -$9.6 million in Q1 2026, -$10.9 million in Q4 2025, and -$8.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Atossa Therapeutics | 23.16 Mn | 23.16 Mn | - | -8.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.49 Mn |
| Mar 31, 2026 | -9.59 Mn |
| Dec 31, 2025 | -10.94 Mn |
| Sep 30, 2025 | -8.69 Mn |
| Jun 30, 2025 | -8.42 Mn |
| Mar 31, 2025 | -6.72 Mn |
| Dec 31, 2024 | -6.35 Mn |
| Sep 30, 2024 | -7.23 Mn |
| Jun 30, 2024 | -6.05 Mn |
| Mar 31, 2024 | -5.88 Mn |
| Dec 31, 2023 | -7.75 Mn |
| Sep 30, 2023 | -6.23 Mn |
| Jun 30, 2023 | -9.83 Mn |
| Mar 31, 2023 | -6.28 Mn |
| Dec 31, 2022 | -7.49 Mn |
| Sep 30, 2022 | -8.01 Mn |
| Jun 30, 2022 | -6.67 Mn |
| Mar 31, 2022 | -4.79 Mn |
| Dec 31, 2021 | -4.83 Mn |
| Sep 30, 2021 | -5.20 Mn |